Clinical Trial Update: Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers [NA]

View source ↗

Summary

Clinical trial update about truncated and extended forms of amyloid beta peptides and their potential as biological markers in Alzheimer’s disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Alzheimer Disease | NA | Status: UNKNOWN